Imatinib (Gleevec): For Ph+ chronic, accelerated, and blastic phases Dasatinib (Sprycel): For newly diagnosed chronic phase, and chronic, accelerated, or myeloid or lymphoid blast phase with resistance or intolerance to prior therapy including imatinib Nilotinib (Tasigna): For newly diagnosed chro...
TARGETED ONCOLOGY:You mentioned identifying prognosis factors. Where are we at right now in terms of doing that? Richter: We looked at a number of factors that have been examined in other trials as well. It doesn't seem that the so-called "risk score" matters in our trial, nor do a...
[CML] PrognosisSkim Re: [CML] PrognosisRob Re: [CML] CCR after 3 months in Phase 2 BMS trialSkim [CML] Bob W's update...longnancy wilhelm Re: [CML] Bob W's update...longRob Re: [CML] Bob W's update...longchoqol...@netzero.com [CML] BMA/PCR resultsBarbara Meunier...
1 Blast phase, which is the most advanced, behaves like an acute leukemia and confers a poor prognosis. CML was the first malignancy whose exact molecular abnormality (BCR-ABL gene) was identified. This led to the development of several targeted therapies against BCR-ABL. This review will ...
Imatinib mesylate (Gleevec, Glivec), a potent and specific inhibitor of the BCR-ABL tyrosine kinase, is now the first-line treatment for CML. Imatinib has significantly improved the prognosis of CML[3]. The International Randomized Study of Interferon and STI571 (IRIS) trial found an estimated...
Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani Met al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells.Cancer2007;110: 1509–1519. ...
2005/08/14Re: [CML] PrognosisRob 2005/08/14Re: [CML] Happy Birthday LaquitaRob 2005/08/14[CML] Question on pcr resultsterrijeff9 2005/08/14[CML] Key process in gene regulation occurs in blood plateletscmlm...@gmail.com 2005/08/14[CML] Immune system discovery offers hope for cancer,...
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia Leukemia, 30 (1) (2016), pp. 48-56 CrossrefView in ScopusGoogle Scholar 54 F Castagnetti, G Gugliotta, M Breccia, et al. The use of the EUTOS long-term survival score is strongly ...